Novartis Reports Results of Kisqali (ribociclib) + Endocrine Therapy in P-III MONALEESA trials for (HR+/HER2-) Advanced Breast Cancer

 Novartis Reports Results of Kisqali (ribociclib) + Endocrine Therapy in P-III MONALEESA trials for (HR+/HER2-) Advanced Breast Cancer

Novartis Reports Results of Kisqali (ribociclib) + Endocrine Therapy in P-III MONALEESA trials for (HR+/HER2-) Advanced Breast Cancer

Shots:

  • The P-III MONALEESA trials (MONALEESA-2, 3,7) involved assessing of Kisqali (ribociclib) + endocrine therapy vs endocrine therapy alone in patients with visceral metastases in pre, peri- and postmenopausal women with HR+/HER2- advanced breast cancer
  • P-III MONALEESA study results: (MONALEESA-2, 3,7) mPFS (11.5 mos., 16.5 mos., 13.4 mos.), mORR (53%, 48%, 50% vs 40%, 31%, 38%); w/o visceral disease ORR (59%, 49%, 52% vs 35%, 39%, 32%)
  • Kisqali (ribociclib) is CDK4/6 (cyclin-dependent kinase) inhibitor and approved in the US & EU for postmenopausal women with HR+/HER2- LA or Mbreast cancer + aromatase inhibitor

Click here to read full press release/ article | Ref: Novartis | Image: The Irish Times

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post